SCHEMBL1105202

SCHEMBL1105202

CCN(CC)c1ccc2cc(C(=O)C(C)C)c(=O)oc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.74
MAPT P10636 8/20 0.74
KMT2A Q03164 8/20 0.74
ALDH1A1 P00352 6/20 0.74
KDM4E B2RXH2 6/20 0.74
HPGD P15428 4/20 0.74
MAOB P27338 3/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
ATM Q13315 3/20 0.74
USP2 O75604 2/20 0.74
HSD17B10 Q99714 2/20 0.74
SLC16A3 O15427 2/20 0.74
CYP1A2 P05177 1/20 0.74
CYP2C19 P33261 1/20 0.74
ALOX15 P16050 1/20 0.74
SLC16A1 P53985 1/20 0.74
CYP19A1 P11511 1/20 0.63
NPSR1 Q6W5P4 2/20 0.57
NPC1 O15118 1/20 0.57
STAT3 P40763 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26552713 0.90 MEN1 (0.60) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL11583085 0.87 MEN1 (0.69) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL51872 0.87 MEN1 (0.82) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL51307 0.85 SLC16A3 (0.72) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL1131018 0.85 MEN1 (1.00) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL30782203 0.85 SLC16A3 (0.72) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL42693 0.85 ALDH1A1 (1.00) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL29775307 0.85 ALDH1A1 (1.00) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL29460450 0.85 MEN1 (1.00) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL25443888 0.84 MEN1 (0.78) MEN1MAPTKMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230229084-A1 CHEMICALLY AMPLIFIED PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE DRY FILM, PRODUCTION METHOD OF SUBSTRATE HAVING TEMPLATE FOR PLATING, AND PRODUCTION METHOD OF PLATED ARTICLE TOKYO OHKA KOGYO CO., LTD. (JP) 2023-07-20 US disclosed
US-20230229084-A1 CHEMICALLY AMPLIFIED PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE DRY FILM, PRODUCTION METHOD OF SUBSTRATE HAVING TEMPLATE FOR PLATING, AND PRODUCTION METHOD OF PLATED ARTICLE TOKYO OHKA KOGYO CO., LTD. (JP) 2023-07-20 US disclosed
US-20230146870-A1 METHOD TO QUANTIFY AFFINITY AND SELECTIVITY OF SMALL MOLECULES FOR PROTEINS IN LIVING CELLS OHIO STATE INNOVATION FOUNDATION 2023-05-11 US disclosed
US-20230146870-A1 METHOD TO QUANTIFY AFFINITY AND SELECTIVITY OF SMALL MOLECULES FOR PROTEINS IN LIVING CELLS OHIO STATE INNOVATION FOUNDATION 2023-05-11 US disclosed
US-20210047329-A1 SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-02-18 US disclosed
US-10869939-B2 Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2020-12-22 US disclosed
US-20170035916-A1 DELIVERY SYSTEM IN MICELLAR FORM HAVING MODULAR SPECTRAL RESPONSE BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID POLYMERS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-02-09 US disclosed
US-20170035916-A1 DELIVERY SYSTEM IN MICELLAR FORM HAVING MODULAR SPECTRAL RESPONSE BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID POLYMERS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-02-09 US disclosed
US-8153393-B2 Spirolactam targeting compounds and related compounds UNIVERSITY OF MASSACHUSETTS (US) 2012-04-10 US disclosed
US-20080233609-A1 Spirolactam Targeting Compounds and Related Compounds UNIVERSITY OF MASSACHUSETTS 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047329-A1 SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES DHPS, QDPR, HTR5A MEN1 1683/4885MAPT 925/4885KMT2A 3531/4885
US-20170035916-A1 DELIVERY SYSTEM IN MICELLAR FORM HAVING MODULAR SPECTRAL RESPONSE BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID POLYMERS JMJD7, HM13, APEH MEN1 396/4885MAPT 3017/4885KMT2A 2838/4885
US-20080233609-A1 Spirolactam Targeting Compounds and Related Compounds AGTR2, AGTR1, REN MEN1 3541/4885MAPT 4118/4885KMT2A 4475/4885
US-10869939-B2 Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers JMJD7, HM13, APEH MEN1 396/4885MAPT 3017/4885KMT2A 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.